We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Harold Bays

Harold Edward Bays MD, FTOS, FACC, FACE, FNLA

Medical Director / President, L-MARC Research Center, Louisville, Kentucky

Dr. Harold Bays is Board Certified in Endocrinology and Internal Medicine, Diplomate of the American Board of Clinical Lipidology, and Diplomate of the American Board of Obesity Medicine.  He has served as an Investigator for over 400 Phase I - IV clinical trials regarding treatments for dyslipidemias, obesity, diabetes mellitus, hypertension, and other metabolic and hormonal disorders. As Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center, Dr. Bays has written, or served as a contributing author to over 200 peer review scientific manuscripts and book chapters, as well as over 100 scientific abstracts presented at major scientific meetings. He is a Fellow of the National Lipid Association (FNLA), Fellow of The Obesity Society (FTOS), Fellow of the American College of Cardiology (FACC) and Fellow of the American Association of Clinical Endocrinologists (FACE). He has served as an advisor/consultant to numerous pharmaceutical companies with regard to drug development, protocol writing, statistical analyses, regulatory application, FDA Advisory panel presentations, and patent assistance. Dr. Bays originated the term "adiposopathy" ("sick fat"), which defines how and when the pathologic consequences of adipose tissue accumulation promotes metabolic disease, including dyslipidemia, diabetes mellitus, and hypertension.  Dr. Bays is Guest Editor and co-author of the National Lipid Association Annual Summary of Clinical Lipidology 2015, co-author of the National Lipid Association Recommendations for Patient-Centered Treatment of Dyslipidemia, and coauthor of the American Society of Bariatric Physicians Obesity Algorithm.  He was Chairman of the National Lipid Association 2012 Adiposity and Dyslipidemia Consensus Conference and Chairman of the 2010 American Association of Clinical Endocrinologist Adipose Tissue Pathophysiology State of the Science Conference.

Disclosures

In the past 12 months, Dr. Harold Bays’ research site has received research grants from Amarin, Amgen, Ardea, Arisaph, Catabasis, Cymabay, Eisai, Elcelyx, Eli Lilly, Esperion, Hanmi, Hisun, Hoffman LaRoche, Home Access, Janssen, Johnson and Johnson, Merck, Necktar, Novartis, Novo Nordisk, Omthera, Orexigen, Pfizer, Pronova, Regeneron, Sanofi, Takeda, TIMI, VIVUS, and Wpu Pharmaceuticals.  In the past 12 months, Dr. Harold Bays has served as a consultant and/or speaker to Alnylam, Amarin, Amgen, Astra Zeneca, Eisai, Eli Lilly, Merck, Novartis, NovoNordisk, Regeneron, Sanofi and Takeda.